Central Nervous System Pharmacology Practice Questions

Q: Which of the following is not an antiepileptic agent?

Flunarizine. **Explanation:** The correct answer is **Flunarizine**. While it is a pharmacological agent acting on the CNS, it is not classified as an antiepileptic drug (AED). **1. Why Flunarizine is the correct answer:** Flunarizine is a **non-selective calcium channel blocker** with additional dopamine D2 receptor blocking activity. Its primary clinical use is in the **prophylaxis of migraine** and the management of vertigo (vestibular disorders). Unlike AEDs, it does not stabilize neuronal membranes against high-frequency firing or enhance GABAergic inhibition to prevent seizures. **2. Why the other options are incorrect:** * **Phenytoin (Option A):** A classic first-generation AED. It works by blocking voltage-gated sodium channels in their inactive state, preventing the spread of seizure activity. * **Topiramate (Option C):** A broad-spectrum AED with multiple mechanisms: blocking sodium channels, enhancing GABA activity, and antagonizing AMPA/kainate glutamate receptors. It is used for both focal/generalized seizures and migraine prophylaxis. * **Carbamazepine (Option D):** An iminostilbene derivative and a first-line agent for focal seizures and trigeminal neuralgia. It works primarily by stabilizing inactivated sodium channels. **Clinical Pearls for NEET-PG:** * **Flunarizine Side Effects:** Can cause **extrapyramidal symptoms (EPS)** and depression due to its D2 blocking property; it is contraindicated in Parkinson’s disease. * **Drug of Choice (DOC):** * Trigeminal Neuralgia: Carbamazepine. * Absence Seizures: Ethosuximide (Valproate if generalized tonic-clonic seizures coexist). * Myoclonic Seizures: Valproate. * **Teratogenicity:** Phenytoin is associated with **Fetal Hydantoin Syndrome**, while Valproate is associated with **Neural Tube Defects**.

Q: What is a known side effect of Levodopa?

On-off phenomenon. **Explanation:** **Levodopa** is the metabolic precursor of dopamine and remains the gold standard for managing Parkinson’s disease. The **"On-off phenomenon"** is a classic long-term complication of Levodopa therapy, typically occurring after 3–5 years of treatment. 1. **Why Option D is Correct:** The "On-off phenomenon" refers to sudden, unpredictable fluctuations in motor performance. The "On" period represents improved mobility (often accompanied by dyskinesias), while the "Off" period involves a sudden return of severe parkinsonian symptoms. This occurs due to the progressive loss of dopaminergic neurons, which reduces the brain's capacity to store dopamine, making the patient's clinical state entirely dependent on the fluctuating plasma levels of the drug. 2. **Why Other Options are Incorrect:** * **A. Spasticity:** This is a feature of Upper Motor Neuron (UMN) lesions. Parkinson’s is an extrapyramidal disorder characterized by **rigidity** (lead-pipe or cogwheel), not spasticity. * **B. Tremor:** Resting tremor is a primary symptom of Parkinson’s disease itself. Levodopa is used to *treat* tremors, not cause them. * **C. Akinesia:** Similar to tremor, akinesia (poverty of movement) is a cardinal symptom of the disease that Levodopa aims to alleviate. **High-Yield NEET-PG Pearls:** * **Peripheral Decarboxylase Inhibitors (Carbidopa/Benserazide):** Always co-administered with Levodopa to prevent peripheral conversion to dopamine, thereby reducing systemic side effects like nausea, vomiting, and cardiac arrhythmias. * **Vitamin B6 (Pyridoxine):** It is a cofactor for DOPA decarboxylase; taking it with Levodopa (without Carbidopa) enhances peripheral metabolism, reducing the drug's efficacy. * **Adverse Effects:** Early effects include GI distress and postural hypotension; late effects include dyskinesias and psychosis.

Q: A 44-year-old male with a history of anxiety treated with alprazolam for 3 years presented with lack of improvement and slurred speech after alcohol consumption. He decided to stop the medication to prevent dependence and was admitted with severe withdrawal symptoms. Which statement regarding alprazolam use is accurate?

All of the above statements are accurate.. This question tests the pharmacological and clinical profile of Benzodiazepines (BZDs), specifically Alprazolam, which is a high-potency, short-acting BZD. **Explanation of the Correct Answer:** The correct answer is **D (All of the above)** because each statement reflects a core pharmacological property of BZDs: * **Option A (Additive CNS Depression):** Both alcohol and BZDs are positive allosteric modulators of the **GABA-A receptor**. When taken together, they produce a synergistic effect on the chloride channel, leading to profound CNS depression, respiratory depression, and symptoms like slurred speech or ataxia. * **Option B (Withdrawal Timeline):** Physical dependence can develop relatively quickly. Abrupt cessation after as little as **3–4 weeks** of regular use can trigger withdrawal symptoms (anxiety, tremors, seizures). Alprazolam is particularly notorious for severe withdrawal due to its short half-life. * **Option C (Tolerance):** Chronic use leads to the downregulation of GABA receptors. Tolerance develops rapidly to the sedative and anticonvulsant effects, though more slowly to the anxiolytic effects. **Why other options are "incorrect":** In a "Multiple Correct" style question, options A, B, and C are individually accurate statements; therefore, they are not "wrong" in a clinical sense, but "D" is the most comprehensive choice. **NEET-PG High-Yield Pearls:** * **Antidote:** Flumazenil is a competitive BZD antagonist used in acute overdose (Note: It can precipitate seizures in chronic users). * **Withdrawal Management:** Always taper BZDs slowly. Switching to a long-acting BZD like **Diazepam** (Chlordiazepoxide is also used) is the preferred strategy for detoxification. * **Alprazolam Specifics:** It is the BZD most commonly associated with "rebound anxiety" and has a high abuse potential due to its rapid onset and short duration.

Q: Which of the following is NOT used for surface anesthesia?

Procaine. **Explanation:** The effectiveness of a local anesthetic (LA) for surface (topical) anesthesia depends on its ability to penetrate mucous membranes or skin. **Why Procaine is the Correct Answer:** Procaine is an ester-linked local anesthetic with **very low lipid solubility** and poor penetrative capacity. Because it cannot effectively cross mucosal barriers, it is virtually ineffective when applied topically. It is primarily used for infiltration anesthesia and was historically used for spinal anesthesia, but it has no role in surface anesthesia. **Analysis of Incorrect Options:** * **Lignocaine (Lidocaine):** The most versatile LA. It has excellent lipid solubility and is widely used for surface anesthesia in various forms (e.g., 2% jelly for catheterization, 4% topical solution for airway blocks, and 10% spray for dental procedures). * **Tetracaine (Amethocaine):** A potent ester LA with high lipid solubility. It is highly effective for surface anesthesia, particularly in ophthalmology (eye drops) and for topical anesthesia of the tracheobronchial tree. * **Benzocaine:** Due to its very low pKa, it exists almost entirely in the unionized form. This makes it highly lipid-soluble but poorly water-soluble. It is used exclusively for surface anesthesia (e.g., lozenges for sore throats, topical gels for mouth ulcers) because it is too toxic for injection. **High-Yield NEET-PG Pearls:** * **Cocaine** is the only naturally occurring local anesthetic and possesses intrinsic vasoconstrictive properties, making it excellent for topical use in ENT surgeries. * **EMLA (Eutectic Mixture of Local Anesthetics):** A 1:1 mixture of 2.5% Lignocaine and 2.5% Prilocaine used to anesthetize intact skin. * **Potency & Duration:** Both are directly proportional to **lipid solubility**. * **Onset of Action:** Inversely proportional to the **pKa** (lower pKa = faster onset).

Q: Which of the following compounds acts as a benzodiazepine antagonist?

Flumazenil. **Explanation:** **Correct Option: A. Flumazenil** Flumazenil is a specific **competitive antagonist** at the benzodiazepine (BZD) binding site on the **GABA-A receptor** complex [1], [2]. It blocks the actions of benzodiazepines and "Z-drugs" (Zolpidem, Zopiclone) but does not affect the actions of barbiturates or alcohol, as they bind to different sites [2], [3]. It is primarily used to reverse BZD-induced sedation for anesthesia or in the management of benzodiazepine overdose [2]. **Incorrect Options:** * **B. Naloxone:** This is a competitive **opioid antagonist** used for the emergency reversal of opioid overdose (e.g., morphine, heroin). It has no effect on GABA receptors. * **C. Furazolidone:** This is a nitrofuran derivative with **antibacterial and antiprotozoal** properties, commonly used for infectious diarrhea and giardiasis. It also possesses mild MAO-inhibitory activity. * **D. Naltrexone:** This is a long-acting **opioid antagonist**. While Naloxone is used for acute reversal, Naltrexone is used for the long-term maintenance of opioid-free states and to reduce cravings in alcohol dependence. **High-Yield Clinical Pearls for NEET-PG:** * **Half-life:** Flumazenil has a very short half-life (~1 hour). Because many benzodiazepines (like Diazepam) have longer half-lives, **re-sedation** can occur, requiring repeated doses or an infusion. * **Seizure Risk:** The most serious side effect of Flumazenil is the induction of **seizures**, especially in patients with long-term BZD dependence or those who have co-ingested tricyclic antidepressants (TCAs) [1]. * **Inverse Agonist:** Do not confuse Flumazenil (antagonist) with **Beta-carbolines**, which act as inverse agonists at the BZD site and can cause convulsions [1].

Q: Which of the following opioids is 100 times more potent than morphine?

Fentanyl. **Explanation:** **Correct Option: B (Fentanyl)** Fentanyl is a synthetic opioid agonist that acts primarily on the $\mu$ (mu) receptors. It is highly lipophilic, allowing it to cross the blood-brain barrier rapidly. In clinical practice, Fentanyl is approximately **100 times more potent than Morphine**. This high potency is due to its high affinity for the $\mu$-receptor and its rapid onset of action. It is commonly used in anesthesia (induction and maintenance) and for chronic pain management via transdermal patches. **Incorrect Options:** * **A & D (Pethidine/Meperidine):** These are the same drug. Pethidine is significantly **less potent** than morphine (roughly 1/10th the potency). It is unique because it has anticholinergic properties (causing tachycardia) and its metabolite, *normeperidine*, can cause seizures in patients with renal failure. * **C (Pentazocine):** This is an opioid agonist-antagonist ( $\kappa$-agonist and weak $\mu$-antagonist/partial agonist). It is much less potent than morphine and can precipitate withdrawal symptoms in opioid-dependent individuals. **High-Yield NEET-PG Pearls:** * **Potency Hierarchy:** Sufentanil (1000x) > Remifentanil/Fentanyl (100x) > Morphine (1x) > Pethidine (0.1x). * **Sufentanil** is the most potent opioid used clinically (500–1000 times more potent than morphine). * **Remifentanil** is notable for its ultra-short duration of action due to metabolism by plasma and tissue esterases. * **Miosis** is a classic sign of opioid overdose, but **Pethidine** is an exception (it may cause mydriasis due to its atropine-like action).

Q: Use of ergotamine is contraindicated in which of the following conditions?

Ischemic heart disease. **Explanation:** **Ergotamine** is an ergot alkaloid that acts as a potent, non-selective agonist at **5-HT1B/1D receptors**. Its primary therapeutic effect in migraine management is mediated through **intense peripheral and cranial vasoconstriction**. **1. Why Ischemic Heart Disease (IHD) is the Correct Answer:** The vasoconstrictive action of ergotamine is not limited to cranial vessels; it also affects the coronary arteries. In patients with IHD, ergotamine can precipitate **coronary vasospasm**, leading to myocardial ischemia, angina, or even myocardial infarction. Therefore, it is strictly contraindicated in IHD, peripheral vascular disease (Raynaud's), and uncontrolled hypertension. **2. Analysis of Incorrect Options:** * **Diabetes Mellitus:** While DM is a risk factor for vascular disease, it is not a direct contraindication unless the patient has documented macrovascular complications (like CAD or PVD). * **Anemia:** There is no direct pharmacological interaction or contraindication between ergotamine use and anemia. * **Postpartum Hemorrhage (PPH):** Ergot derivatives (specifically **Methylergometrine**) are actually *indicated* in PPH to promote uterine contraction. While ergotamine itself is not the first-line ergot for PPH, it is not contraindicated. **3. High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** 5-HT1B/1D agonist → Vasoconstriction + inhibition of neurogenic inflammation. * **Ergotism (St. Anthony’s Fire):** Toxicity characterized by severe peripheral ischemia (gangrene) and CNS stimulation (hallucinations). * **Drug Interaction:** Ergotamine metabolism is inhibited by **CYP3A4 inhibitors** (e.g., Ritonavir, Erythromycin), which can lead to life-threatening ischemia. * **Triptans vs. Ergots:** Both are contraindicated in IHD due to coronary vasoconstriction.

Q: All of the following are true about Triptans except:

They act by inhibiting 5HT 1B / 1D receptors.. The core mechanism of Triptans involves **agonism**, not inhibition. Triptans are selective **5-HT$_{1B/1D}$ receptor agonists** [1, 2]. Their therapeutic effect in migraine is mediated through three mechanisms:1. **Vasoconstriction:** Activation of 5-HT$_{1B}$ receptors on intracranial blood vessels reverses vasodilation [1].2. **Neuropeptide Inhibition:** Activation of 5-HT$_{1D}$ receptors on trigeminal nerve endings inhibits the release of pro-inflammatory peptides (like CGRP and Substance P) [2].3. **Central Inhibition:** They inhibit pain transmission in the trigeminal nucleus caudalis.#### Analysis of Options:* **Option D (Correct):** This is the false statement. Triptans **stimulate** (act as agonists) rather than inhibit these receptors.* **Option A:** Triptans are indeed the **Drug of Choice (DOC)** for moderate-to-severe acute migraine attacks when NSAIDs fail [1].* **Option B:** **Frovatriptan** has the longest half-life (~26 hours), making it useful for preventing menstrual migraine [3].* **Option C:** **Sumatriptan** is the prototype and is available via oral, nasal, and **subcutaneous** routes [1, 3]. The SC route offers the fastest onset of action (approx. 10–15 mins) [3].#### High-Yield NEET-PG Pearls:* **Fastest acting triptan:** Rizatriptan (oral) or Sumatriptan (SC) [3].* **Contraindications:** Since they cause vasoconstriction, they are strictly contraindicated in patients with **Ischemic Heart Disease (IHD)**, Prinzmetal angina, and uncontrolled hypertension [3].* **Sumatriptan** has the lowest oral bioavailability among the group.* **Almotriptan** has the best oral bioavailability.

Q: Baclofen is used in which of the following conditions?

Spasticity. **Explanation:** **Baclofen** is a centrally acting skeletal muscle relaxant that acts as a selective **GABA-B receptor agonist**. It works by increasing potassium conductance, leading to hyperpolarization of neurons. This inhibits both monosynaptic and polysynaptic reflexes at the spinal cord level, effectively reducing muscle tone and frequency of spasms. * **Why Spasticity is Correct:** Baclofen is the drug of choice for managing **spasticity** associated with spinal cord injuries, multiple sclerosis, and amyotrophic lateral sclerosis (ALS). It is preferred because it causes less sedation compared to benzodiazepines. **Analysis of Incorrect Options:** * **Parkinsonism:** This is a movement disorder caused by dopamine deficiency in the nigrostriatal pathway. Treatment involves dopaminergic agents (Levodopa) or anticholinergics, not GABA agonists. * **Epilepsy:** Baclofen is generally **avoided** in patients with epilepsy as it can lower the seizure threshold and potentially worsen the condition. * **Stroke:** While stroke can lead to spasticity (upper motor neuron lesion), Baclofen is less effective for spasticity of cerebral origin compared to spinal origin. Furthermore, it is not a primary treatment for the stroke itself. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** GABA-B agonist (G-protein coupled receptor). * **Administration:** Can be given orally or via an **intrathecal pump** for severe refractory spasticity. * **Withdrawal Warning:** Abrupt discontinuation of Baclofen can lead to life-threatening withdrawal symptoms, including hallucinations, seizures, and rebound spasticity. * **Comparison:** Unlike Dantrolene (which acts directly on the muscle/Ryanodine receptors), Baclofen acts on the **spinal cord**.

Question 1

Which of the following is not an antiepileptic agent?

Accepted Answer

Flunarizine

Answer

Phenytoin

Answer

Topiramate

Answer

Carbamazepine

Question 2

Which of the following adverse effects of levodopa is not minimized even after combining it with carbidopa?

Accepted Answer

Involuntary movements

Answer

Nausea and vomiting

Answer

Cardiac arrhythmia

Answer

'On-off' effect

Question 3

What is a known side effect of Levodopa?

Accepted Answer

On-off phenomenon

Answer

Spasticity

Answer

Tremor

Answer

Akinesia

Question 4

A 44-year-old male with a history of anxiety treated with alprazolam for 3 years presented with lack of improvement and slurred speech after alcohol consumption. He decided to stop the medication to prevent dependence and was admitted with severe withdrawal symptoms. Which statement regarding alprazolam use is accurate?

Accepted Answer

All of the above statements are accurate.

Answer

Additive CNS depression occurs with ethanol.

Answer

Abrupt discontinuance of alprazolam after 4 weeks of treatment may elicit withdrawal signs.

Answer

Tolerance can occur with chronic use of any benzodiazepine.

Question 5

Which of the following is NOT used for surface anesthesia?

Accepted Answer

Procaine

Answer

Lignocaine

Answer

Tetracaine

Answer

Benzocaine

Question 6

Which of the following compounds acts as a benzodiazepine antagonist?

Accepted Answer

Flumazenil

Answer

Naloxone

Answer

Furazolidone

Answer

Naltrexone

Question 7

Which of the following opioids is 100 times more potent than morphine?

Accepted Answer

Fentanyl

Answer

Pethidine

Answer

Pentazocine

Answer

Meperidine

Question 8

Use of ergotamine is contraindicated in which of the following conditions?

Accepted Answer

Ischemic heart disease

Answer

Diabetes Mellitus

Answer

Anemia

Answer

Postpartum hemorrhage

Question 9

All of the following are true about Triptans except:

Accepted Answer

They act by inhibiting 5HT 1B / 1D receptors.

Answer

They are the drug of choice in the acute attack of migraine.

Answer

Frovatriptan is the longest acting triptan.

Answer

Sumatriptan can also be given subcutaneously.

Question 10

Baclofen is used in which of the following conditions?

Accepted Answer

Spasticity

Answer

Parkinsonism

Answer

Epilepsy

Answer

Stroke

Central Nervous System Pharmacology — MCQs

Central Nervous System Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?